Sign Out
Hypersensitivity to active substance or to any of the excipients.
Concomitant use of Cymbalta with nonselective, irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated (see Interactions).
Liver disease resulting in hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Cymbalta should not be used in combination with fluvoxamine, ciprofloxacin or enoxacine (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see Interactions).
Severe renal impairment (creatine clearance <30 mL/min) (see Precautions).
The initiation of treatment with Cymbalta is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see Precautions and Adverse Reactions).
